FI964189A0 - Immunogeeniset ryhmä A-streptokokkaaliset polysakkaridikoostumukset ja menetelmät - Google Patents

Immunogeeniset ryhmä A-streptokokkaaliset polysakkaridikoostumukset ja menetelmät

Info

Publication number
FI964189A0
FI964189A0 FI964189A FI964189A FI964189A0 FI 964189 A0 FI964189 A0 FI 964189A0 FI 964189 A FI964189 A FI 964189A FI 964189 A FI964189 A FI 964189A FI 964189 A0 FI964189 A0 FI 964189A0
Authority
FI
Finland
Prior art keywords
group
immunogenic
polysaccharide
methods
streptococcal
Prior art date
Application number
FI964189A
Other languages
English (en)
Swedish (sv)
Other versions
FI118514B (fi
FI964189A (fi
Inventor
Milan S Blake
John B Zabriskie
Joseph Y Tai
Francis Michon
Original Assignee
Univ Rockefeller
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, North American Vaccine Inc filed Critical Univ Rockefeller
Publication of FI964189A0 publication Critical patent/FI964189A0/fi
Publication of FI964189A publication Critical patent/FI964189A/fi
Application granted granted Critical
Publication of FI118514B publication Critical patent/FI118514B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
FI964189A 1994-04-21 1996-10-18 A-ryhmän streptokokin polysakkaridi, immunogeeniset koostumukset ja menetelmät FI118514B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/231,229 US5866135A (en) 1994-04-21 1994-04-21 Group A streptococcal polysaccharide immunogenic compositions and methods
US23122994 1994-04-21
US9504973 1995-04-20
PCT/US1995/004973 WO1995028960A1 (en) 1994-04-21 1995-04-20 Group a streptococcal polysaccharide immunogenic compositions and methods

Publications (3)

Publication Number Publication Date
FI964189A0 true FI964189A0 (fi) 1996-10-18
FI964189A FI964189A (fi) 1996-12-18
FI118514B FI118514B (fi) 2007-12-14

Family

ID=22868303

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964189A FI118514B (fi) 1994-04-21 1996-10-18 A-ryhmän streptokokin polysakkaridi, immunogeeniset koostumukset ja menetelmät

Country Status (17)

Country Link
US (2) US5866135A (fi)
EP (1) EP0754055B1 (fi)
JP (1) JPH09512276A (fi)
CN (1) CN1159064C (fi)
AT (1) ATE196605T1 (fi)
AU (1) AU709797B2 (fi)
BR (1) BR9507400A (fi)
CA (1) CA2188284C (fi)
DE (1) DE69518978T2 (fi)
DK (1) DK0754055T3 (fi)
ES (1) ES2151597T3 (fi)
FI (1) FI118514B (fi)
GR (1) GR3034916T3 (fi)
NO (1) NO321321B1 (fi)
PL (1) PL181037B1 (fi)
PT (1) PT754055E (fi)
WO (1) WO1995028960A1 (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
EP1087791B1 (en) * 1998-04-15 2005-09-21 Mayo Foundation for Medical Education and Research Inhibition of xenoreactive antibodies
DE60038166T2 (de) * 1999-03-19 2009-03-12 Glaxosmithkline Biologicals S.A., Rixensart Impfstoff gegen bakterielle antigene
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
NZ553554A (en) * 2000-06-20 2008-11-28 Id Biomedical Corp Streptococcus antigens
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US20020192205A1 (en) * 2001-05-11 2002-12-19 Francis Michon Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
US7534442B2 (en) * 2001-08-21 2009-05-19 The Brigham And Women's Hospital, Inc. Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
WO2004009770A2 (en) * 2002-07-19 2004-01-29 The Regents Of The University Of California Methods and compositions for modulating agonist-induced downregulation of g protein-coupled receptors
US20040197845A1 (en) * 2002-08-30 2004-10-07 Arjang Hassibi Methods and apparatus for pathogen detection, identification and/or quantification
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2621359T3 (es) * 2007-06-20 2017-07-03 Pfizer Ireland Pharmaceuticals Polisacáridos modificados para vacunas conjugadas
EP2045201A1 (en) * 2007-10-02 2009-04-08 M T C - Macchine Trasformazione Carta S.r.l. Rewinding method and rewinding machine that carries out this method
US20100136041A1 (en) * 2008-09-17 2010-06-03 Novartis Ag Combination gas vaccines and therapeutics
JP5689064B2 (ja) * 2008-10-27 2015-03-25 ノバルティス アーゲー 精製方法
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
EP2356135B1 (en) 2008-11-05 2017-10-25 Wyeth LLC Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
US20130149331A1 (en) * 2011-05-03 2013-06-13 Peng George Wang Rhamnose and forssman conjugated immunogenic agents
WO2013020090A2 (en) 2011-08-04 2013-02-07 The Regents Of The University Of California STREPTOCOCCAL GLcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
BR112020004509A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
US11590079B2 (en) * 2018-01-18 2023-02-28 EndoProtech, Inc. Treating microvascular dysfunction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods

Also Published As

Publication number Publication date
DE69518978D1 (de) 2000-11-02
EP0754055B1 (en) 2000-09-27
CN1159064C (zh) 2004-07-28
NO321321B1 (no) 2006-04-24
CA2188284C (en) 2001-04-17
BR9507400A (pt) 1997-10-07
FI118514B (fi) 2007-12-14
AU709797B2 (en) 1999-09-09
DK0754055T3 (da) 2000-12-18
DE69518978T2 (de) 2001-03-15
US7332173B2 (en) 2008-02-19
ES2151597T3 (es) 2001-01-01
CA2188284A1 (en) 1995-11-02
US20050163808A1 (en) 2005-07-28
AU2296795A (en) 1995-11-16
ATE196605T1 (de) 2000-10-15
NO964413D0 (no) 1996-10-17
FI964189A (fi) 1996-12-18
GR3034916T3 (en) 2001-02-28
CN1149835A (zh) 1997-05-14
JPH09512276A (ja) 1997-12-09
PT754055E (pt) 2001-02-28
US5866135A (en) 1999-02-02
NO964413L (no) 1996-12-17
EP0754055A1 (en) 1997-01-22
WO1995028960A1 (en) 1995-11-02
PL316906A1 (en) 1997-02-17
PL181037B1 (pl) 2001-05-31

Similar Documents

Publication Publication Date Title
FI964189A0 (fi) Immunogeeniset ryhmä A-streptokokkaaliset polysakkaridikoostumukset ja menetelmät
BR0009166A (pt) Vacina
IL115047A (en) Immunogenic conjugates comprising pneumococcal polysaccharide and recombinant pneumolysin, vaccines comprising such conjugates and use of such vaccines in the manufacture of medicaments for immunizing against pneumococcal infections
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
BR0114785A (pt) Composição adjuvante, composição de vacina, e, métodos para desviar, a qualidade de uma resposta imunológica contra um antìgeno, para a manufatura de uma composição de vacina, e para tratar um indivìduo suscetìvel a ou sofrendo de uma doença.
CY1110140T1 (el) Εμβολιασμος με μηνιγγοκοκκικο συζευγμα
JP6266631B2 (ja) 免疫原性組成物
LU90809I2 (fr) Vaccin comprenant des saccharides pneumococciques de serotypes 4,6b,9v,14,18c19f et 23f, chacun d'entre eux conjugu- avec une prot-ine porteuse crm 197
LU91610I2 (fr) Protéine D et ses dérivés pharmaceutiquement acceptables (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé)
RU2004136295A (ru) Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку
WO2002032923A3 (en) Improved formulations using heat shock/stress protein-peptide complexes
WO2002092131A3 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
WO2022101745A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
FR2646776B1 (fr) Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
Yakushiji et al. Purification and immunochemical studies of type b carbohydrate antigen of oral Streptococcus milleri
MX9709732A (es) Vacuna que comprende un conjugado de antigeno de polisacarido proteina portadora y proteina portadora libre.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118514

Country of ref document: FI